Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Ordinary Shares, no par value per share
-
Shares outstanding
-
112,245,592
-
Total 13F shares
-
95,188,552
-
Share change
-
+3,292,222
-
Total reported value
-
$1,696,317,176
-
Put/Call ratio
-
12%
-
Price per share
-
$17.82
-
Number of holders
-
224
-
Value change
-
+$20,032,618
-
Number of buys
-
107
-
Number of sells
-
122
Institutional Holders of NovoCure Ltd - Ordinary Shares, no par value per share (NVCR) as of Q1 2025
As of 31 Mar 2025,
NovoCure Ltd - Ordinary Shares, no par value per share (NVCR) was held by
224 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
95,188,552 shares.
The largest 10 holders included
FMR LLC, BlackRock, Inc., VANGUARD GROUP INC, Capital International Investors, Soleus Capital Management, L.P., Capital World Investors, STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, MARSHALL WACE, LLP, and UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC.
This page lists
224
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.